Therefore, these results suggest that MARCO+ TAMs could restrain the MHC‐I machinery and compromise the antigen cross‐presentation and tumor‐recognition capacity of TAMs, thereby impeding CD8+ CTL immunity in RCC. The gene discussed is MARCO; the disease is renal cell adenocarcinoma.